AbbVie Inc (ABBV) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Total Revenue Chart for AbbVie Inc

AbbVie Inc (ABBV) revenue for FY2025 was USD 61.2B, a 8.6% change from FY2024. AbbVie Inc's revenue grew from USD 14.2B in 2009 to USD 61.2B in 2025 (330.3% over 16 years). Earnings per share grew from USD 2.57 in 2010 to USD 6.66 in 2022 (158.9%). Revenue compound annual growth rate: 5-year CAGR of 6.0%, 10-year CAGR of 10.3%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$430.95B
Implied Share Price
$243.87
Enterprise Value
$506.83B
Revenue (TTM)
$64.39B
EBITDA
$30.76B
Profit Margin
9.80%
Trailing P/E
69.48
Forward P/E
17.79
Price/Book (MRQ)
50.46
Price/Sales (TTM)
6.69
EV/EBITDA
44.16
EV/Revenue
7.87
Dividend Yield
2.77%
Book Value
$-3.36
Free Cash Flow (FY2025)
$17.82B
Free Cash Flow Yield
4.13%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.